BIOSYNEX (EPA:ALBIO) | WebDisclosure

Basculer en Français

10371	Companies
216158	Keywords
145874	Articles
114457	Press releases

Home
Companies
BIOSYNEX

PRESS RELEASE

published on 02/06/2026 at 08:00, 3 months 2 days ago

BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, REÇOIT UNE SUBVENTION DE $1,8 MILLION DE CARB-X POUR LE DÉVELOPPEMENT D'UN TEST DE DIAGNOSTIC RAPIDE DE LA FIEVRE TYPHOIDE
CARB-X accorde à la filiale de BIOSYNEX, CHEMBIO DIAGNOSTIC SYSTEMS, une subvention de $1,8 million pour développer un test rapide de diagnostic de la fièvre typhoïde

Subvention BIOSYNEX Chembio Diagnostic Systems CARB-X Fièvre Typhoïde
BRIEF

published on 01/22/2026 at 18:05, 3 months 17 days ago

BIOSYNEX announces dual FDA filing for an innovative syphilis test

FDA BIOSYNEX DPP® Syphilis TnT Test Syphilis Detection Innovative Device
BRIEF

published on 01/22/2026 at 18:05, 3 months 17 days ago

BIOSYNEX annonce un double dépôt à la FDA pour un test syphilis innovant

FDA BIOSYNEX Test DPP® Syphilis TNT Détection Syphilis Dispositif Innovant
PRESS RELEASE

published on 01/22/2026 at 18:00, 3 months 17 days ago

BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, ANNONCE LE DOUBLE DÉPÔT À LA FDA DU TEST DPP® SYPHILIS TnT SUITE À LA DÉSIGNATION DE DISPOSITIF INNOVANT (BREAKTHROUGH DEVICE)
Chembio Diagnostic Systems Inc., filiale de Biosynex, dépose le test DPP® Syphilis TnT auprès de la FDA suite à la désignation d'appareil innovant (Breakthrough Device) pour le diagnostic de la syphilis

FDA BIOSYNEX Chembio Diagnostic Systems Dispositif Innovant Test DPP Syphilis TnT
BRIEF

published on 01/15/2026 at 18:05, 3 months 24 days ago

BIOSYNEX SA: 2025 Review and Outlook for 2026

Revenue Restructuring BIOSYNEX Outlook 2026 Thermotherapy
BRIEF

published on 01/15/2026 at 18:05, 3 months 24 days ago

BIOSYNEX SA : Bilan 2025 et Perspectives pour 2026

Chiffre D'affaires Restructuration BIOSYNEX Perspectives 2026 Thermothérapie
PRESS RELEASE

published on 01/15/2026 at 18:00, 3 months 24 days ago

BIOSYNEX SA: ACTIVITE 2025 - PERSPECTIVES 2026
BIOSYNEX SA annonce une baisse de 6% de son chiffre d'affaires en 2025 et présente ses perspectives pour 2026, mettant l'accent sur le redressement de son activité et le déploiement de nouveaux produits

Chiffre D'affaires Restructuration BIOSYNEX SA Perspectives 2026 Activité 2025
BRIEF

published on 01/06/2026 at 18:05, 4 months 2 days ago

BIOSYNEX SA dévoile son calendrier financier pour 2026

Calendrier Financier Résultats BIOSYNEX Tests Rapides 2026
BRIEF

published on 01/06/2026 at 18:05, 4 months 2 days ago

BIOSYNEX SA unveils its financial calendar for 2026

Financial Calendar Results BIOSYNEX Rapid Tests 2026
PRESS RELEASE

published on 01/06/2026 at 18:00, 4 months 2 days ago

BIOSYNEX SA: Calendrier financier 2026
BIOSYNEX annonce son calendrier financier 2026 pour les rapports annuels et trimestriels. Le leader du diagnostic de santé offre des solutions innovantes en biologie moléculaire

Calendrier Financier BIOSYNEX Diagnostic De Santé Tests Rapides Biologie Moléculaire

Accesswire

Published on 05/09/2026 at 00:00, 36 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 hour 35 minutes ago

Water Ways Announces Corporate Updates
Published on 05/08/2026 at 23:00, 1 hour 36 minutes ago

Digi Power X Announces Upsizing of At-the-Market Offering Program
Published on 05/08/2026 at 22:30, 2 hours 6 minutes ago

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Published on 05/08/2026 at 22:30, 2 hours 6 minutes ago

Sekur Private Data Advances Defense-Grade Secure Communications Platform

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 20:38, 3 hours 58 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 5 hours 23 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 5 hours 34 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 6 hours 7 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 6 hours 7 minutes ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 1 day 5 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 5 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 5 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 5 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE